A small peptide to protect brain connections in Alzheimer's-related dementias
A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD)
This study is testing a new treatment for older adults with Alzheimer's-related dementias that targets multiple harmful proteins in the brain to help protect memory and thinking skills.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Creative Bio-Peptides, INC. NIH-funded |
| Lab location | 1 site (Potomac, United States) |
| Project ID | NIH-11158833 on NIH RePORTER |
What this research studies
This research investigates a novel small peptide aimed at treating mixed proteinopathies, specifically targeting the co-occurrence of alpha-synuclein, amyloid beta, and tau proteins in Alzheimer's disease-related dementias. The approach focuses on mitigating synapse loss, which is crucial for memory and cognitive function, by using chemokine receptor antagonists that have shown promise in previous studies. By addressing multiple underlying causes of neurodegeneration simultaneously, the research aims to provide a more effective treatment strategy for patients over 65 suffering from these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's disease-related dementias.
Not a fit: Patients under the age of 65 or those with other forms of dementia not related to mixed proteinopathies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that slows down or prevents cognitive decline in patients with Alzheimer's-related dementias.
How similar studies have performed: Previous research has indicated that targeting multiple proteinopathies can be an effective strategy, suggesting potential success for this novel approach.
Where this research is happening
Potomac, United States
- Creative Bio-Peptides, INC. — Potomac, United States (Active)
Researchers
- Principal investigator: Ruff, Michael R — Creative Bio-Peptides, INC.
- Study coordinator: Ruff, Michael R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.